Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.
Acetylcysteine was granted FDA approval on 14 September 1963.
Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.
Unversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Royal Brompton Hospital, London, United Kingdom
U.Z. Ghent, Gent, Belgium
Hôpital A. Calmette, Lille Cedex, France
Klinikum Grosshadern, Munich, Germany
Rijnstate Hospital, Arnhem, Gelderland, Netherlands
Oregon Health & Science University, Portland, Oregon, United States
"San Giovanni Battista" Hospital of Turin, Turin, Italy
Minneapolis VA Medical Center, Minneapolis, Minnesota, United States
Clinical Research Facility, Royal Infirmary Edinburgh, Edinburgh, Midlothian, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.